Dual Role of Exosome in Neurodegenerative Diseases: A Review Study

Mohsen      Sheykhhasan; Fatemeh      Heidari; Mohsen      Eslami Farsani; Maryam      Azimzadeh; Naser      Kalhor; Shima      Ababzadeh; Reihaneh      Seyedebrahimi
doi:10.2174/1574888X18666230726161035
Abstract

Introduction: Extracellular vesicles (EVs) are one of the crucial means of intercellular communication, which takes many different forms. They are heterogeneous, secreted by a range of cell types, and can be generally classified into microvesicles and exosomes depending on their location and function. Exosomes are small EVs with diameters of about 30–150 nm and diverse cell sources.
Methods: The MEDLINE/PubMed database was reviewed for papers written in English and publication dates of recent years, using the search string "Exosome" and "Neurodegenerative diseases."
Results: The exosomes have attracted interest as a significant biomarker for a better understanding of disease development, gene silencing delivery, and alternatives to stem cell-based therapy because of their low-invasive therapeutic approach, repeatable distribution in the central nervous system (CNS), and high efficiency. Also, they are nanovesicles that carry various substances, which can have an impact on neural plasticity and cognitive functioning in both healthy and pathological circumstances. Therefore, exosomes are conceived as nanovesicles containing proteins, lipids, and nucleic acids. However, their composition varies considerably depending on the cells from which they are produced.
Conclusion: In the present review, we discuss several techniques for the isolation of exosomes from different cell sources. Furthermore, reviewing research on exosomes' possible functions as carriers of bioactive substances implicated in the etiology of neurodegenerative illnesses, we further examine them. We also analyze the preclinical and clinical research that shows exosomes to have therapeutic potential.
Keywords: Exosome, multiple sclerosis, alzheimer’s disease, parkinson’s disease, huntington’s disease, addiction.
« Previous Next »
Graphical Abstract

[1]
Beck S, Hochreiter B, Schmid JA. Extracellular vesicles linking inflammation, cancer and thrombotic risks. Front Cell Dev Biol  2022; 10: 859863.
 [http://dx.doi.org/10.3389/fcell.2022.859863] [PMID:  35372327]

[2]
Gupta D, Zickler AM, El Andaloussi S. Dosing extracellular vesicles. Adv Drug Deliv Rev  2021; 178: 113961.
 [http://dx.doi.org/10.1016/j.addr.2021.113961] [PMID:  34481030]

[3]
Jeppesen DK, Zhang Q, Franklin JL, Coffey RJ. Extracellular vesicles and nanoparticles: Emerging complexities. Trends Cell Biol  2023; S0962-8924(23): 00005-3.
 [PMID: 36737375]

[4]
Chung IM, Rajakumar G, Venkidasamy B, Subramanian U, Thiruvengadam M. Exosomes: Current use and future applications. Clin Chim Acta  2020; 500: 226-32.
 [http://dx.doi.org/10.1016/j.cca.2019.10.022] [PMID:  31678573]

[5]
Doyle L, Wang M. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells  2019; 8(7): 727-9.
 [http://dx.doi.org/10.3390/cells8070727] [PMID:  31311206]

[6]
Kim YS, Ahn JS, Kim S, Kim HJ, Kim SH, Kang JS. The potential theragnostic (diagnostic+therapeutic) application of exosomes in diverse biomedical fields. Korean J Physiol Pharmacol  2018; 22(2): 113-25.
 [http://dx.doi.org/10.4196/kjpp.2018.22.2.113] [PMID:  29520164]

[7]
Wan R, Hussain A, Behfar A, Moran SL, Zhao C. The therapeutic potential of exosomes in soft tissue repair and regeneration. Int J Mol Sci  2022; 23(7): 3869.
 [http://dx.doi.org/10.3390/ijms23073869] [PMID:  35409228]

[8]
Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem  1987; 262(19): 9412-20.
 [http://dx.doi.org/10.1016/S0021-9258(18)48095-7] [PMID:  3597417]

[9]
Chen J, Zhang Q, Liu D, Liu Z. Exosomes: Advances, development and potential therapeutic strategies in diabetic nephropathy. Metabolism  2021; 122: 154834.
 [http://dx.doi.org/10.1016/j.metabol.2021.154834] [PMID:  34217734]

[10]
Elahi FM, Farwell DG, Nolta JA, Anderson JD. Preclinical translation of exosomes derived from mesenchymal stem/stromal cells. Stem Cells  2020; 38(1): 15-21.
 [http://dx.doi.org/10.1002/stem.3061] [PMID:  31381842]

[11]
Allan D, Tieu A, Lalu M, Burger D. Mesenchymal stromal cell-derived extracellular vesicles for regenerative therapy and immune modulation: Progress and challenges toward clinical application. Stem Cells Transl Med  2020; 9(1): 39-46.
 [http://dx.doi.org/10.1002/sctm.19-0114] [PMID:  31411820]

[12]
Wu R, Gao W, Yao K, Ge J. Roles of exosomes derived from immune cells in cardiovascular diseases. Front Immunol  2019; 10: 648-51.
 [http://dx.doi.org/10.3389/fimmu.2019.00648] [PMID:  30984201]

[13]
Aheget H, Tristán-Manzano M, Mazini L, et al. Exosome: A new player in translational nanomedicine. J Clin Med  2020; 9(8): 2380.
 [http://dx.doi.org/10.3390/jcm9082380] [PMID:  32722531]

[14]
Li N, Zhao L, Wei Y, Ea VL, Nian H, Wei R. Recent advances of exosomes in immune-mediated eye diseases. Stem Cell Res Ther  2019; 10(1): 278.
 [http://dx.doi.org/10.1186/s13287-019-1372-0] [PMID:  31470892]

[15]
Nojehdehi S, Soudi S, Hesampour A, Rasouli S, Soleimani M, Hashemi SM. Immunomodulatory effects of mesenchymal stem cell–derived exosomes on experimental type 1 autoimmune diabetes. J Cell Biochem  2018; 119(11): 9433-43.
 [http://dx.doi.org/10.1002/jcb.27260] [PMID:  30074271]

[16]
Cho BS, Kim JO, Ha DH, Yi YW. Exosomes derived from human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis. Stem Cell Res Ther  2018; 9(1): 187.
 [http://dx.doi.org/10.1186/s13287-018-0939-5] [PMID:  29996938]

[17]
Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science  2020; 367(6478): eaau6977.
 [http://dx.doi.org/10.1126/science.aau6977] [PMID:  32029601]

[18]
Jiang L, Dong H, Cao H, Ji X, Luan S, Liu J. Exosomes in pathogenesis, diagnosis, and treatment of Alzheimer’s disease. Med Sci Monit  2019; 25: 3329-35.
 [http://dx.doi.org/10.12659/MSM.914027] [PMID:  31056537]

[19]
Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol  2007; 9(6): 654-9.
 [http://dx.doi.org/10.1038/ncb1596] [PMID:  17486113]

[20]
Farooqi AA, Desai NN, Qureshi MZ, et al. Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds. Biotechnol Adv  2018; 36(1): 328-34.
 [http://dx.doi.org/10.1016/j.biotechadv.2017.12.010] [PMID:  29248680]

[21]
Li XX, Yang LX, Wang C, Li H, Shi DS, Wang J. The roles of exosomal proteins: Classification, function, and applications. Int J Mol Sci  2023; 24(4): 3061.
 [http://dx.doi.org/10.3390/ijms24043061] [PMID:  36834471]

[22]
Hedayat M, Ahmadi M, Shoaran M, Rezaie J. Therapeutic application of mesenchymal stem cells derived exosomes in neurodegenerative diseases: A focus on non-coding RNAs cargo, drug delivery potential, perspective. Life Sci  2023; 320: 121566.
 [http://dx.doi.org/10.1016/j.lfs.2023.121566] [PMID:  36907326]

[23]
Salvioli S, Olivieri F, Marchegiani F, et al. Genes, ageing and longevity in humans: Problems, advantages and perspectives. Free Radic Res  2006; 40(12): 1303-23.
 [http://dx.doi.org/10.1080/10715760600917136] [PMID:  17090420]

[24]
Pedersen SF, Ho YC. SARS-CoV-2: A storm is raging. J Clin Invest  2020; 130(5): 2202-5.
 [http://dx.doi.org/10.1172/JCI137647] [PMID:  32217834]

[25]
Kordelas L, Rebmann V, Ludwig A-K, et al. MSC-derived exosomes: A novel tool to treat therapy-refractory graft-versus-host disease. Leukemia  2014; 28(4): 970-3.
 [http://dx.doi.org/10.1038/leu.2014.41] [PMID:  24445866]

[26]
Phinney DG. Functional heterogeneity of mesenchymal stem cells: Implications for cell therapy. J Cell Biochem  2012; 113(9): 2806-12.
 [http://dx.doi.org/10.1002/jcb.24166] [PMID:  22511358]

[27]
Huang R, Qin C, Wang J, et al. Differential effects of extracellular vesicles from aging and young mesenchymal stem cells in acute lung injury. Aging  2019; 11(18): 7996-8014.
 [http://dx.doi.org/10.18632/aging.102314] [PMID:  31575829]

[28]
Yuan L, Li JY. Exosomes in Parkinson’s disease: Current perspectives and future challenges. ACS Chem Neurosci  2019; 10(2): 964-72.
 [http://dx.doi.org/10.1021/acschemneuro.8b00469] [PMID:  30664350]

[29]
Dai J, Su Y, Zhong S, et al. Exosomes: Key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther  2020; 5(1): 145.
 [http://dx.doi.org/10.1038/s41392-020-00261-0] [PMID:  32759948]

[30]
Castaño C, Kalko S, Novials A, Párrizas M. Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. Proc Natl Acad Sci  2018; 115(48): 12158-63.
 [http://dx.doi.org/10.1073/pnas.1808855115] [PMID:  30429322]

[31]
Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles  2015; 4(1): 30087.
 [http://dx.doi.org/10.3402/jev.v4.30087] [PMID:  26725829]

[32]
Sun Y, Shi H, Yin S, et al. Human mesenchymal stem cell derived exosomes alleviate type 2 diabetes mellitus by reversing peripheral insulin resistance and relieving β-cell destruction. ACS Nano  2018; 12(8): 7613-28.
 [http://dx.doi.org/10.1021/acsnano.7b07643] [PMID:  30052036]

[33]
Rezaie J, Feghhi M, Etemadi T. A review on exosomes application in clinical trials: Perspective, questions, and challenges. Cell Commun Signal  2022; 20(1): 145.
 [http://dx.doi.org/10.1186/s12964-022-00959-4] [PMID:  36123730]

[34]
Corradetti B, Gonzalez D, Mendes Pinto I, Conlan RS. Editorial: Exosomes as therapeutic systems. Front Cell Dev Biol  2021; 9: 714743.
 [http://dx.doi.org/10.3389/fcell.2021.714743] [PMID:  34368165]

[35]
Hussen BM, Faraj GSH, Rasul MF, et al. Strategies to overcome the main challenges of the use of exosomes as drug carrier for cancer therapy. Cancer Cell Int  2022; 22(1): 323-7.
 [http://dx.doi.org/10.1186/s12935-022-02743-3] [PMID:  36258195]

[36]
Weng S, Lai QL, Wang J, et al. The role of exosomes as mediators of neuroinflammation in the pathogenesis and treatment of Alzheimer’s disease. Front Aging Neurosci  2022; 14: 899944.
 [http://dx.doi.org/10.3389/fnagi.2022.899944] [PMID:  35837481]

[37]
Gandham S, Su X, Wood J, et al. Technologies and standardization in research on extracellular vesicles. Trends Biotechnol  2020; 38(10): 1066-98.
 [http://dx.doi.org/10.1016/j.tibtech.2020.05.012] [PMID:  32564882]

[38]
Willms E, Cabañas C, Mäger I, Wood MJA, Vader P. Extracellular vesicle heterogeneity: Subpopulations, isolation techniques, and diverse functions in cancer progression. Front Immunol  2018; 9: 738-41.
 [http://dx.doi.org/10.3389/fimmu.2018.00738] [PMID:  29760691]

[39]
Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in exosome isolation techniques. Theranostics  2017; 7(3): 789-804.
 [http://dx.doi.org/10.7150/thno.18133] [PMID:  28255367]

[40]
Karimi N, Cvjetkovic A, Jang SC, et al. Detailed analysis of the plasma extracellular vesicle proteome after separation from lipoproteins. Cell Mol Life Sci  2018; 75(15): 2873-86.
 [http://dx.doi.org/10.1007/s00018-018-2773-4] [PMID:  29441425]

[41]
Yang D, Zhang W, Zhang H, et al. Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics. Theranostics  2020; 10(8): 3684-707.
 [http://dx.doi.org/10.7150/thno.41580] [PMID:  32206116]

[42]
Chen J, Li P, Zhang T, et al. Review on strategies and technologies for exosome isolation and purification. Front Bioeng Biotechnol  2022; 9: 811971.
 [http://dx.doi.org/10.3389/fbioe.2021.811971] [PMID:  35071216]

[43]
Liangsupree T, Multia E, Riekkola ML. Modern isolation and separation techniques for extracellular vesicles. J Chromatogr A  2021; 1636: 461773.
 [http://dx.doi.org/10.1016/j.chroma.2020.461773] [PMID:  33316564]

[44]
Sidhom K, Obi PO, Saleem A. A review of exosomal isolation methods: Is size exclusion chromatography the best option? Int J Mol Sci  2020; 21(18): 6466.
 [http://dx.doi.org/10.3390/ijms21186466] [PMID:  32899828]

[45]
Talebjedi B, Tasnim N, Hoorfar M, Mastromonaco GF, De Almeida Monteiro Melo Ferraz M. Exploiting microfluidics for extracellular vesicle isolation and characterization: Potential use for standardized embryo quality assessment. Front Vet Sci  2021; 7: 620809.
 [http://dx.doi.org/10.3389/fvets.2020.620809] [PMID:  33469556]

[46]
Singh PK, Patel A, Kaffenes A, Hord C, Kesterson D, Prakash S. Microfluidic approaches and methods enabling extracellular vesicle isolation for cancer diagnostics. Micromachines  2022; 13(1): 139.
 [http://dx.doi.org/10.3390/mi13010139] [PMID:  35056304]

[47]
Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab  2012; 32(11): 1959-72.
 [http://dx.doi.org/10.1038/jcbfm.2012.126] [PMID:  22929442]

[48]
Tomlinson PR, Zheng Y, Fischer R, et al. Identification of distinct circulating exosomes in Parkinson’s disease. Ann Clin Transl Neurol  2015; 2(4): 353-61.
 [http://dx.doi.org/10.1002/acn3.175] [PMID:  25909081]

[49]
Heidarzadeh M, Gürsoy-Özdemir Y, Kaya M, et al. Exosomal delivery of therapeutic modulators through the blood–brain barrier; promise and pitfalls. Cell Biosci  2021; 11(1): 142.
 [http://dx.doi.org/10.1186/s13578-021-00650-0] [PMID:  34294165]

[50]
Huang Y, Liu Z, Li N, et al. Parkinson’s disease derived exosomes aggravate neuropathology inSNCA * A53T Mice. Ann Neurol  2022; 92(2): 230-45.
 [http://dx.doi.org/10.1002/ana.26421] [PMID:  35596947]

[51]
Sun K, Zheng X, Jin H, Yu F, Zhao W. Exosomes as CNS drug delivery tools and their applications. Pharmaceutics  2022; 14(10): 2252.
 [http://dx.doi.org/10.3390/pharmaceutics14102252] [PMID:  36297688]

[52]
Khan SU, Khan MU, Gao Y, et al. Unique therapeutic potentialities of exosomes based nanodrug carriers to target tumor microenvironment in cancer therapy. OpenNano  2022; 8: 100091.
 [http://dx.doi.org/10.1016/j.onano.2022.100091]

[53]
Khan SU, Khan MI, Khan MU, Khan NM, Bungau S, Hassan SS. Applications of extracellular vesicles in nervous system disorders: An overview of recent advances. Bioengineering  2022; 10(1): 51.
 [http://dx.doi.org/10.3390/bioengineering10010051] [PMID:  36671622]

[54]
Suire CN, Hade MD. Extracellular vesicles in type 1 diabetes: A versatile tool. Bioengineering  2022; 9(3): 105-10.
 [http://dx.doi.org/10.3390/bioengineering9030105] [PMID:  35324794]

[55]
Holm MM, Kaiser J, Schwab ME. Extracellular vesicles: Multimodal envoys in neural maintenance and repair. Trends Neurosci  2018; 41(6): 360-72.
 [http://dx.doi.org/10.1016/j.tins.2018.03.006] [PMID:  29605090]

[56]
Delpech JC, Herron S, Botros MB, Ikezu T. Neuroimmune crosstalk through extracellular vesicles in health and disease. Trends Neurosci  2019; 42(5): 361-72.
 [http://dx.doi.org/10.1016/j.tins.2019.02.007] [PMID:  30926143]

[57]
Li Z, Liu F, He X, Yang X, Shan F, Feng J. Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia. Int Immunopharmacol  2019; 67: 268-80.
 [http://dx.doi.org/10.1016/j.intimp.2018.12.001] [PMID:  30572251]

[58]
Farinazzo A, Angiari S, Turano E, et al. Nanovesicles from adipose-derived mesenchymal stem cells inhibit T lymphocyte trafficking and ameliorate chronic experimental autoimmune encephalomyelitis. Sci Rep  2018; 8(1): 7473.
 [http://dx.doi.org/10.1038/s41598-018-25676-2] [PMID:  29748664]

[59]
Elia CA, Tamborini M, Rasile M, et al. Intracerebral injection of extracellular vesicles from mesenchymal stem cells exerts reduced Aβ plaque burden in early stages of a preclinical model of alzheimer’s disease. Cells  2019; 8(9): 1059.
 [http://dx.doi.org/10.3390/cells8091059] [PMID:  31510042]

[60]
Zhuang X, Xiang X, Grizzle W, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther  2011; 19(10): 1769-79.
 [http://dx.doi.org/10.1038/mt.2011.164] [PMID:  21915101]

[61]
Jahangard Y, Monfared H, Moradi A, Zare M, Mirnajafi-Zadeh J, Mowla SJ. Therapeutic effects of transplanted exosomes containing miR-29b to a rat model of Alzheimer’s disease. Front Neurosci  2020; 14: 564.
 [http://dx.doi.org/10.3389/fnins.2020.00564] [PMID:  32625049]

[62]
Mobahat M, Sadroddiny E, Nooshabadi VT, Ebrahimi-Barough S, Goodarzi A, Malekshahi ZV, et al. Curcumin-loaded human endometrial stem cells derived exosomes as an effective carrier to suppress alpha-synuclein aggregates in 6OHDA-induced Parkinson’s disease mouse model. Cell Tissue Bank  2022; 24(1): 75-91.
 [PMID:  35641803]

[63]
Xue C, Li X, Ba L, et al. MSC-derived exosomes can enhance the angiogenesis of human brain MECs and show therapeutic potential in a mouse model of Parkinson’s disease. Aging Dis  2021; 12(5): 1211-22.
 [http://dx.doi.org/10.14336/AD.2020.1221] [PMID:  34341703]

[64]
Sun T, Ding ZX, Luo X, Liu QS, Cheng Y. Blood exosomes have neuroprotective effects in a mouse model of Parkinson’s disease. Oxid Med Cell Longev  2020; 2020: 1-14.
 [http://dx.doi.org/10.1155/2020/3807476] [PMID:  33294121]

[65]
Lee M, Liu T, Im W, Kim M. Exosomes from adipose-derived stem cells ameliorate phenotype of Huntington’s disease in vitro model. Eur J Neurosci  2016; 44(4): 2114-9.
 [http://dx.doi.org/10.1111/ejn.13275] [PMID:  27177616]

[66]
Lee ST, Im W, Ban JJ, et al. Exosome-based delivery of miR-124 in a Huntington’s disease model. J Mov Disord  2017; 10(1): 45-52.
 [http://dx.doi.org/10.14802/jmd.16054] [PMID:  28122430]

[67]
Joshi BS, Youssef SA, Bron R. DNAJB6-enriched exosomes decrease polyglutamine aggregation in in vitro and in vivo models of Huntington’s disease. iScience  2021; 163-6.

[68]
Zhou Y, Xiao S, Li C, Chen Z, Zhu C, Zhou Q, et al. Extracellular vesicle-encapsulated miR-183-5p from rhynchophylline-treated H9c2 cells protect against methamphetamine-induced dependence in mouse brain by targeting NRG1. Evid Based Complement Alternat Med  2021; 2021: 2136076.
 [http://dx.doi.org/10.1155/2021/2136076] [PMID:  34484386]

[69]
Ezquer F, Quintanilla ME, Morales P, et al. Intranasal delivery of mesenchymal stem cell-derived exosomes reduces oxidative stress and markedly inhibits ethanol consumption and post-deprivation relapse drinking. Addict Biol  2019; 24(5): 994-1007.
 [http://dx.doi.org/10.1111/adb.12675] [PMID:  30239077]

[70]
Azimzadeh M, Möhn N, Ghane Ezabadi S, et al. The immunological therapeutic strategies for controlling multiple sclerosis: Considerations during the covid-19 pandemic. Biomolecules  2021; 11(9): 1372.
 [http://dx.doi.org/10.3390/biom11091372] [PMID:  34572585]

[71]
Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: Mechanisms and immunotherapy. Neuron  2018; 97(4): 742-68.
 [http://dx.doi.org/10.1016/j.neuron.2018.01.021] [PMID:  29470968]

[72]
Pusic AD, Pusic KM, Kraig RP. What are exosomes and how can they be used in multiple sclerosis therapy? Expert Rev Neurother  2014; 14(4): 353-5.
 [http://dx.doi.org/10.1586/14737175.2014.890893] [PMID:  24552578]

[73]
Baharlooi H, Salehi Z, Minbashi Moeini M, Rezaei N, Azimi M. Immunomo sis. Adv Pharm Bull  2022; 12(2): 389-97.
 [PMID:  35620339]

[74]
Riazifar M, Mohammadi MR, Pone EJ, et al. Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders. ACS Nano  2019; 13(6): 6670-88.
 [http://dx.doi.org/10.1021/acsnano.9b01004] [PMID:  31117376]

[75]
Zhang J, Buller BA, Zhang ZG, et al. Exosomes derived from bone marrow mesenchymal stromal cells promote remyelination and reduce neuroinflammation in the demyelinating central nervous system. Exp Neurol  2022; 347: 113895.
 [http://dx.doi.org/10.1016/j.expneurol.2021.113895] [PMID:  34653510]

[76]
Gupta D, Wiklander OPB, Görgens A, Conceição M, Corso G, Liang X, et al. Engineering of extracellular vesicles for display of protein biotherapeutics. bioRxiv  2020; 2021: 149823.
 [http://dx.doi.org/10.1101/2020.06.14.149823]

[77]
Zheng X, Sun K, Liu Y, et al. Resveratrol-loaded macrophage exosomes alleviate multiple sclerosis through targeting microglia. J Control Release  2023; 353: 675-84.
 [http://dx.doi.org/10.1016/j.jconrel.2022.12.026] [PMID:  36521687]

[78]
Fayazi N, Sheykhhasan M, Soleimani Asl S, Najafi R. Stem cell-derived exosomes: A new strategy of neurodegenerative disease treatment. Mol Neurobiol  2021; 58(7): 3494-514.
 [http://dx.doi.org/10.1007/s12035-021-02324-x] [PMID:  33745116]

[79]
Hosseini Shamili F, Alibolandi M, Rafatpanah H, et al. Immunomodulatory properties of MSC-derived exosomes armed with high affinity aptamer toward mylein as a platform for reducing multiple sclerosis clinical score. J Control Release  2019; 299: 149-64.
 [http://dx.doi.org/10.1016/j.jconrel.2019.02.032] [PMID:  30807806]

[80]
Wu XY, Liao BY, Xiao D, et al. Encapsulation of bryostatin-1 by targeted exosomes enhances remyelination and neuroprotection effects in the cuprizone-induced demyelinating animal model of multiple sclerosis. Biomater Sci  2022; 10(3): 714-27.
 [http://dx.doi.org/10.1039/D1BM01142A] [PMID:  34928285]

[81]
Kimura K, Hohjoh H, Yamamura T. The role for exosomal microRNAs in disruption of regulatory T cell homeostasis in multiple sclerosis. J Exp Neurosci  2018; 12.
 [http://dx.doi.org/10.1177/1179069518764892] [PMID:  29623002]

[82]
Ebrahimkhani S, Vafaee F, Young PE, et al. Exosomal microRNA signatures in multiple sclerosis reflect disease status. Sci Rep  2017; 7(1): 14293.
 [http://dx.doi.org/10.1038/s41598-017-14301-3] [PMID:  29084979]

[83]
Gandhi R, Healy B, Gholipour T, et al. Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol  2013; 73(6): 729-40.
 [http://dx.doi.org/10.1002/ana.23880] [PMID:  23494648]

[84]
Manna I, Iaccino E, Dattilo V, et al. Exosome associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. FASEB J  2018; 32(8): 4241-6.
 [http://dx.doi.org/10.1096/fj.201701533R] [PMID:  29505299]

[85]
Ebrahimkhani S, Beadnall HN, Wang C, et al. Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment. Mol Neurobiol  2020; 57(2): 1245-58.
 [http://dx.doi.org/10.1007/s12035-019-01792-6] [PMID:  31721043]

[86]
Mrad MF, Saba ES, Nakib L, Khoury SJ. Exosomes from subjects with multiple sclerosis express EBV-derived proteins and activate monocyte-derived macrophages. Neurol Neuroimmunol Neuroinflamm  2021; 8(4): e1004.
 [http://dx.doi.org/10.1212/NXI.0000000000001004] [PMID:  34006621]

[87]
Ising C, Heneka MT. Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration. Cell Death Dis  2018; 9(2): 120.
 [http://dx.doi.org/10.1038/s41419-017-0153-x] [PMID:  29371603]

[88]
Khan TK, Alkon DL. Peripheral biomarkers of Alzheimer’s disease. J Alzheimers Dis  2015; 44(3): 729-44.
 [http://dx.doi.org/10.3233/JAD-142262] [PMID:  25374110]

[89]
Beker M, Gunay N, Sarikamis B, et al. Dual action of exosomes derived from in vitro Aβ toxicity model: The role of age for pathological response. Arch Gerontol Geriatr  2023; 106: 104874.
 [http://dx.doi.org/10.1016/j.archger.2022.104874] [PMID:  36470179]

[90]
Takahashi RH, Milner TA, Li F, et al. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol  2002; 161(5): 1869-79.
 [http://dx.doi.org/10.1016/S0002-9440(10)64463-X] [PMID:  12414533]

[91]
Saman S, Kim W, Raya M, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem  2012; 287(6): 3842-9.
 [http://dx.doi.org/10.1074/jbc.M111.277061] [PMID:  22057275]

[92]
Fiandaca MS, Kapogiannis D, Mapstone M, et al. Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case control study. Alzheimers Dement  2015; 11(6): 600-7.e1.
 [http://dx.doi.org/10.1016/j.jalz.2014.06.008] [PMID:  25130657]

[93]
Lark DS, LaRocca TJ. Expression of exosome biogenesis genes is differentially altered by aging in the mouse and in the human brain during Alzheimer’s Disease. J Gerontol A Biol Sci Med Sci  2022; 77(4): 659-63.
 [http://dx.doi.org/10.1093/gerona/glab322] [PMID:  34687299]

[94]
Chen YA, Lu CH, Ke CC, et al. Mesenchymal stem cell-derived exosomes ameliorate Alzheimer’s disease pathology and improve cognitive deficits. Biomedicines  2021; 9(6): 594.
 [http://dx.doi.org/10.3390/biomedicines9060594] [PMID:  34073900]

[95]
Soares Martins T, Trindade D, Vaz M, et al. Diagnostic and therapeutic potential of exosomes in Alzheimer’s disease. J Neurochem  2021; 156(2): 162-81.
 [http://dx.doi.org/10.1111/jnc.15112] [PMID:  32618370]

[96]
Nakano M, Fujimiya M. Potential effects of mesenchymal stem cell derived extracellular vesicles and exosomal miRNAs in neurological disorders. Neural Regen Res  2021; 16(12): 2359-66.
 [http://dx.doi.org/10.4103/1673-5374.313026] [PMID:  33907007]

[97]
Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol  2011; 29(4): 341-5.
 [http://dx.doi.org/10.1038/nbt.1807] [PMID:  21423189]

[98]
Cone AS, Yuan X, Sun L, et al. Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer’s disease-like phenotypes in a preclinical mouse model. Theranostics  2021; 11(17): 8129-42.
 [http://dx.doi.org/10.7150/thno.62069] [PMID:  34373732]

[99]
Cheng L, Doecke JD, Sharples RA, et al. Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry  2015; 20(10): 1188-96.
 [http://dx.doi.org/10.1038/mp.2014.127] [PMID:  25349172]

[100]
Gui Y, Liu H, Zhang L, Lv W, Hu X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget  2015; 6(35): 37043-53.
 [http://dx.doi.org/10.18632/oncotarget.6158] [PMID:  26497684]

[101]
Dong Z, Gu H, Guo Q, et al. Circulating small extracellular vesicle-derived miR-342-5p ameliorates beta-amyloid formation via targeting beta-site APP cleaving enzyme 1 in Alzheimer’s Disease. Cells  2022; 11(23): 3830.
 [http://dx.doi.org/10.3390/cells11233830] [PMID:  36497090]

[102]
Goetzl EJ, Kapogiannis D, Schwartz JB, et al. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease. FASEB J  2016; 30(12): 4141-8.
 [http://dx.doi.org/10.1096/fj.201600816R] [PMID:  27601437]

[103]
Liang X, Fa W, Wang N, Peng Y, Liu C, Zhu M, et al. Exosomal miR-532-5p induced by long-term exercise rescues blood-brain barrier function in 5XFAD mice via downregulation of EPHA4. Aging Cell  2023; 22(1): e13748.
 [http://dx.doi.org/10.1111/acel.13748.] [PMID: 36494892]

[104]
Cai H, Pang Y, Wang Q, et al. Proteomic profiling of circulating plasma exosomes reveals novel biomarkers of Alzheimer’s disease. Alzheimers Res Ther  2022; 14(1): 181-6.
 [http://dx.doi.org/10.1186/s13195-022-01133-1] [PMID:  36471423]

[105]
Wang S, Cesca F, Loers G, et al. Synapsin I is an oligomannose-carrying glycoprotein, acts as an oligomannose-binding lectin, and promotes neurite outgrowth and neuronal survival when released via glia-derived exosomes. J Neurosci  2011; 31(20): 7275-90.
 [http://dx.doi.org/10.1523/JNEUROSCI.6476-10.2011] [PMID:  21593312]

[106]
Lotfy A, AboQuella NM, Wang H. Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther  2023; 14(1): 66-71.
 [http://dx.doi.org/10.1186/s13287-023-03287-7] [PMID:  37024925]

[107]
Charvin D, Medori R, Hauser RA, Rascol O. Therapeutic strategies for Parkinson disease: Beyond dopaminergic drugs. Nat Rev Drug Discov  2018; 17(11): 804-22.
 [http://dx.doi.org/10.1038/nrd.2018.136] [PMID:  30262889]

[108]
Yu H, Sun T, An J, et al. Potential roles of exosomes in Parkinson’s disease: From pathogenesis, diagnosis, and treatment to prognosis. Front Cell Dev Biol  2020; 8: 86.
 [http://dx.doi.org/10.3389/fcell.2020.00086] [PMID:  32154247]

[109]
Stuendl A, Kunadt M, Kruse N, et al. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies. Brain  2016; 139(2): 481-94.
 [http://dx.doi.org/10.1093/brain/awv346] [PMID:  26647156]

[110]
Shi M, Liu C, Cook TJ, et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol  2014; 128(5): 639-50.
 [http://dx.doi.org/10.1007/s00401-014-1314-y] [PMID:  24997849]

[111]
Grey M, Dunning CJ, Gaspar R, et al. Acceleration of α-synuclein aggregation by exosomes. J Biol Chem  2015; 290(5): 2969-82.
 [http://dx.doi.org/10.1074/jbc.M114.585703] [PMID:  25425650]

[112]
de Rus Jacquet A, Tancredi JL, Lemire AL, DeSantis MC, Li WP, O’Shea EK. The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson’s disease. eLife  2021; 10: e73062.
 [http://dx.doi.org/10.7554/eLife.73062] [PMID:  34590578]

[113]
Mysiris DS, Vavougios GD, Karamichali E, et al. Post-COVID-19 parkinsonism and parkinson’s disease pathogenesis: The exosomal cargo hypothesis. Int J Mol Sci  2022; 23(17): 9739.
 [http://dx.doi.org/10.3390/ijms23179739] [PMID:  36077138]

[114]
Zhang P, Rasheed M, Liang J, Wang C, Feng L, Chen Z. Emerging potential of exosomal Non-coding RNA in Parkinson’s Disease: A review. Front Aging Neurosci  2022; 14: 819836.
 [http://dx.doi.org/10.3389/fnagi.2022.819836] [PMID:  35360206]

[115]
Nila IS, Sumsuzzman DM, Khan ZA, et al. Identification of exosomal biomarkers and its optimal isolation and detection method for the diagnosis of Parkinson’s disease: A systematic review and meta-analysis. Ageing Res Rev  2022; 82: 101764.
 [http://dx.doi.org/10.1016/j.arr.2022.101764] [PMID:  36273807]

[116]
Jiang T, Xu C, Gao S, Zhang J, Zheng J, Wu X, et al. Cathepsin Lcontaining exosomes from α-synuclein-activated microglia induce neurotoxicity through the P2X7 receptor. NPJ Parkinsons Dis  2022; 8(1): 127.
 [http://dx.doi.org/10.1038/s41531-022-00394-9.] [PMID: 36202834]

[117]
Peng H, Li Y, Ji W, et al. Intranasal administration of self-oriented nanocarriers based on therapeutic exosomes for synergistic treatment of parkinson’s disease. ACS Nano  2022; 16(1): 869-84.
 [http://dx.doi.org/10.1021/acsnano.1c08473] [PMID:  34985280]

[118]
Chen Z, Xu C, Li G, Wen Z, Liu J, Mao Z. Neuron-derived exosomes trigger a PD-L1-mediated broad suppression of T cells in Parkinson’s disease. Res Square 2022.
 [http://dx.doi.org/10.21203/rs.3.rs-2109216/v1]

[119]
Lee HK, Finniss S, Cazacu S, Xiang C, Brodie C. Mesenchymal stem cells deliver exogenous miRNAs to neural cells and induce their differentiation and glutamate transporter expression. Stem Cells Dev  2014; 23(23): 2851-61.
 [http://dx.doi.org/10.1089/scd.2014.0146] [PMID:  25036385]

[120]
Qu M, Lin Q, Huang L, et al. Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease. J Control Release  2018; 287: 156-66.
 [http://dx.doi.org/10.1016/j.jconrel.2018.08.035] [PMID:  30165139]

[121]
McColgan P, Tabrizi SJ. Huntington’s disease: A clinical review. Eur J Neurol  2018; 25(1): 24-34.
 [http://dx.doi.org/10.1111/ene.13413] [PMID:  28817209]

[122]
Dayalu P, Albin RL. Huntington Disease. Neurol Clin  2015; 33(1): 101-14.
 [http://dx.doi.org/10.1016/j.ncl.2014.09.003] [PMID:  25432725]

[123]
Hong Y, Zhao T, Li XJ, Li S. Mutant huntingtin inhibits αB-crystallin expression and impairs exosome secretion from astrocytes. J Neurosci  2017; 37(39): 9550-63.
 [http://dx.doi.org/10.1523/JNEUROSCI.1418-17.2017] [PMID:  28893927]

[124]
Didiot MC, Hall LM, Coles AH, et al. Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing. Mol Ther  2016; 24(10): 1836-47.
 [http://dx.doi.org/10.1038/mt.2016.126] [PMID:  27506293]

[125]
Lee M, Im W, Kim M. Exosomes as a potential messenger unit during heterochronic parabiosis for amelioration of Huntington’s disease. Neurobiol Dis  2021; 155: 105374.
 [http://dx.doi.org/10.1016/j.nbd.2021.105374] [PMID:  33940179]

[126]
Barbagallo C, Mostile G, Baglieri G, et al. Specific signatures of serum miRNAs as potential biomarkers to discriminate clinically similar neurodegenerative and vascular-related diseases. Cell Mol Neurobiol  2020; 40(4): 531-46.
 [http://dx.doi.org/10.1007/s10571-019-00751-y] [PMID:  31691877]

[127]
Rani P, Karthik S. Molecular signatures in exosomes as diagnostic markers for neurodegenerative disorders. Ann Alzheimers Dement Care  2020; 4(1): 012-7.

[128]
Ananbeh H, Vodicka P, Kupcova Skalnikova H. Emerging roles of exosomes in Huntington’s Disease. Int J Mol Sci  2021; 22(8): 4085.
 [http://dx.doi.org/10.3390/ijms22084085] [PMID:  33920936]

[129]
Cao X, Pfaff SL, Gage FH. A functional study of miR-124 in the developing neural tube. Genes Dev  2007; 21(5): 531-6.
 [http://dx.doi.org/10.1101/gad.1519207] [PMID:  17344415]

[130]
Sukhanova A, Bozrova S, Sokolov P, Berestovoy M, Karaulov A, Nabiev I. Dependence of nanoparticle toxicity on their physical and chemical properties. Nanoscale Res Lett  2018; 13(1): 44.
 [http://dx.doi.org/10.1186/s11671-018-2457-x] [PMID:  29417375]

[131]
Kranzler HR, Li T-K. What is addiction? Alcohol Res Health  2008; 31(2): 93-5.
 [PMID:  23584810]

[132]
Cooper S, Robison AJ, Mazei-Robison MS. Reward circuitry in addiction. Neurotherapeutics  2017; 14(3): 687-97.
 [http://dx.doi.org/10.1007/s13311-017-0525-z] [PMID:  28324454]

[133]
Kumar A, Kim S, Su Y, et al. Brain cell-derived exosomes in plasma serve as neurodegeneration biomarkers in male cynomolgus monkeys self-administrating oxycodone. EBioMedicine  2021; 63: 103192.
 [http://dx.doi.org/10.1016/j.ebiom.2020.103192] [PMID:  33418508]

[134]
Anthony IC, Norrby KE, Dingwall T, et al. Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers. Brain  2010; 133(12): 3685-98.
 [http://dx.doi.org/10.1093/brain/awq263] [PMID:  21126996]

[135]
Dominy SS, Brown JN, Ryder MI, Gritsenko M, Jacobs JM, Smith RD. Proteomic analysis of saliva in HIV-positive heroin addicts reveals proteins correlated with cognition. PLoS One  2014; 9(4): e89366.
 [http://dx.doi.org/10.1371/journal.pone.0089366] [PMID:  24717448]

[136]
Shahjin F, Guda RS, Schaal VL, et al. Brain-derived extracellular vesicle microRNA signatures associated with in utero and postnatal oxycodone exposure. Cells  2019; 9(1): 21-5.
 [http://dx.doi.org/10.3390/cells9010021] [PMID:  31861723]

[137]
Hollander JA. Striatal microRNA controls cocaine intake through CREB signalling. Nature  2010; 466(7303): 197-202.

[138]
Carone C, Genedani S, Leo G, Filaferro M, Fuxe K, Agnati LF. in vitro effects of cocaine on tunneling nanotube formation and extracellular vesicle release in glioblastoma cell cultures. J Mol Neurosci  2015; 55(1): 42-50.
 [http://dx.doi.org/10.1007/s12031-014-0365-9] [PMID:  24996625]

[139]
Liu Y, Li D, Liu Z, et al. Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse. Sci Rep  2015; 5(1): 17543.
 [http://dx.doi.org/10.1038/srep17543] [PMID:  26633001]

[140]
Sheykhhasan M, Amini R, Soleimani Asl S, Saidijam M, Hashemi SM, Najafi R. Neuroprotective effects of coenzyme Q10-loaded exosomes obtained from adipose-derived stem cells in a rat model of Alzheimer's disease. Biomed Pharmacother  2022; 152: 113224. Epub 2022 Jun 6.
 [http://dx.doi.org/10.1016/j.biopha.2022.113224] [PMID:  35679720]
Rights & Permissions Print Cite
Article Metrics
28
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1574888X18666230726161035	Print ISSN 1574-888X
Publisher Name Bentham Science Publisher	Online ISSN 2212-3946
Current Stem Cell Research & Therapy

Dual Role of Exosome in Neurodegenerative Diseases: A Review Study

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles
